Close Menu

NEW YORK – Myriad Genetics said on Monday that its revenues for the three months ended Sept. 30 declined 22 percent year over year.

Total revenues for the period were $145.2 million, down from $186.3 million. It beat the consensus Wall Street estimate of $135.2 million.

The Salt Lake City-based firm is in the process of changing its financial year to match the calendar year and did not identify the quarter ending on Sept. 30.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.